{"analyses":[{"ciLowerLimit":"0.2","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.8","estimateComment":"The Kaplan Meier method was used to estimate the median PFS (in months) for the population. The Greenwood method was used to estimate the confidence limits of the median progression free survival.","groupIds":["OG000"],"nonInferiorityComment":"Estimation only","nonInferiorityType":"OTHER","paramType":"Median","paramValue":"1.5"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.2","upperLimit":"1.8","value":"1.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"PFS was defined as duration of time from enrollment to the study to time of progression or death. Disease progression (PD) can be objectively determined as per RECIST v1.1 (Response Evaluation Criteria in Solid Tumors, where PD is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in non-target lesion, or the appearance of new lesions) or progression can be subjective as determined by the investigator. Evidence for subjective progressions must be documented in medical records. For surviving subjects who do not have documented PD, PFS will be censored at last radiologic assessment. For subjects who receive subsequent anti-cancer therapy prior to documented PD, PFS will be censored at last radiologic assessment prior to commencement of subsequent therapy. Subjects who experience a PFS event following an interval equal to two or more scheduled assessments will be censored at date of last assessment prior to first missed assessment.","dispersionType":"95% Confidence Interval","groups":[{"description":"This group contains all subjects enrolled on the study, who received crizotinib, pooling the subjects in the three molecularly defined cohorts.","id":"OG000","title":"Total Enrolled Study Cohort"}],"paramType":"MEDIAN","populationDescription":"Study was designed to evaluate outcomes overall for all enrolled subjects and not separately by molecular cohorts. Efficacy analyses were conducted on the population of subjects who began crizotinib treatment.","reportingStatus":"POSTED","timeFrame":"From date of treatment start to date of progression or death, or censored as described above; assessed for approximately 2 years.","title":"Progression Free Survival","type":"SECONDARY","unitOfMeasure":"months"}